Role of Bile Acids in Inflammatory Liver Diseases

Overview

Journal Semin Immunopathol

Publisher Springer

Specialties Allergy & Immunology
Pathology

Date 2021 Jul 8

PMID 34236487

Citations 32

Authors

Ioannis Evangelakos

Joerg Heeren

Esther Verkade

Folkert Kuipers

Affiliations

Soon will be listed here.

Abstract

Bile acids and their signaling pathways are increasingly recognized as potential therapeutic targets for cholestatic and metabolic liver diseases. This review summarizes new insights in bile acid physiology, focusing on regulatory roles of bile acids in the control of immune regulation and on effects of pharmacological modulators of bile acid signaling pathways in human liver disease. Recent mouse studies have highlighted the importance of the interactions between bile acids and gut microbiome. Interfering with microbiome composition may be beneficial for cholestatic and metabolic liver diseases by modulating formation of secondary bile acids, as different bile acid species have different signaling functions. Bile acid receptors such as FXR, VDR, and TGR5 are expressed in a variety of cells involved in innate as well as adaptive immunity, and specific microbial bile acid metabolites positively modulate immune responses of the host. Identification of Cyp2c70 as the enzyme responsible for the generation of hydrophilic mouse/rat-specific muricholic acids has allowed the generation of murine models with a human-like bile acid composition. These novel mouse models will aid to accelerate translational research on the (patho)physiological roles of bile acids in human liver diseases .

Citing Articles

Hepatic Lamp2a deficiency promotes inflammation of murine autoimmune cholangitis via affecting bile acid metabolism.

Fan Q, Guo G, Hu Y, Lu Y, Su R, Yang J iScience. 2025; 28(2):111804.

PMID: 39995863 PMC: 11849667. DOI: 10.1016/j.isci.2025.111804.

Molecular mechanisms in liver repair and regeneration: from physiology to therapeutics.

Ma X, Huang T, Chen X, Li Q, Liao M, Fu L Signal Transduct Target Ther. 2025; 10(1):63.

PMID: 39920130 PMC: 11806117. DOI: 10.1038/s41392-024-02104-8.

Molecular Mechanisms of Fibrosis in Cholestatic Liver Diseases and Regenerative Medicine-Based Therapies.

Wang W, Lian H, Liang Y, Ye Y, Tam P, Chen Y Cells. 2024; 13(23).

PMID: 39682745 PMC: 11640075. DOI: 10.3390/cells13231997.

Fecal deoxycholic acid associates with diet, intestinal microbes, and total bilirubin in primary sclerosing cholangitis.

Chan C, Lemos M, Finnegan P, Gagnon W, Dean R, Yazdanafar M JHEP Rep. 2024; 6(12):101188.

PMID: 39624235 PMC: 11609371. DOI: 10.1016/j.jhepr.2024.101188.

Unlocking gut-liver-brain axis communication metabolites: energy metabolism, immunity and barriers.

Sun X, Shukla M, Wang W, Li S NPJ Biofilms Microbiomes. 2024; 10(1):136.

PMID: 39587086 PMC: 11589602. DOI: 10.1038/s41522-024-00610-9.

References

Groen A, Kuipers F . Bile acid look-alike controls life span in C. elegans. Cell Metab. 2013; 18(2):151-2. DOI: 10.1016/j.cmet.2013.07.009. View

Fiorucci S, Distrutti E, Carino A, Zampella A, Biagioli M . Bile acids and their receptors in metabolic disorders. Prog Lipid Res. 2021; 82:101094. DOI: 10.1016/j.plipres.2021.101094. View

Honda A, Miyazaki T, Iwamoto J, Hirayama T, Morishita Y, Monma T . Regulation of bile acid metabolism in mouse models with hydrophobic bile acid composition. J Lipid Res. 2019; 61(1):54-69. PMC: 6939601. DOI: 10.1194/jlr.RA119000395. View

Neuschwander-Tetri B, Loomba R, Sanyal A, Lavine J, Van Natta M, Abdelmalek M . Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2014; 385(9972):956-65. PMC: 4447192. DOI: 10.1016/S0140-6736(14)61933-4. View

Cameron R, Blendis L, Neuman M . Accumulation of macrophages in primary sclerosing cholangitis. Clin Biochem. 2001; 34(3):195-201. DOI: 10.1016/s0009-9120(01)00215-6. View

Gulamhusein A, Hirschfield G . Primary biliary cholangitis: pathogenesis and therapeutic opportunities. Nat Rev Gastroenterol Hepatol. 2019; 17(2):93-110. DOI: 10.1038/s41575-019-0226-7. View

Glaser F, John C, Engel B, Hoh B, Weidemann S, Dieckhoff J . Liver infiltrating T cells regulate bile acid metabolism in experimental cholangitis. J Hepatol. 2019; 71(4):783-792. DOI: 10.1016/j.jhep.2019.05.030. View

de Boer J, de Vries H, Palmiotti A, Li R, Doestzada M, Hoogerland J . Cholangiopathy and Biliary Fibrosis in Cyp2c70-Deficient Mice Are Fully Reversed by Ursodeoxycholic Acid. Cell Mol Gastroenterol Hepatol. 2020; 11(4):1045-1069. PMC: 7898074. DOI: 10.1016/j.jcmgh.2020.12.004. View

Bechmann L, Hannivoort R, Gerken G, Hotamisligil G, Trauner M, Canbay A . The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol. 2011; 56(4):952-64. DOI: 10.1016/j.jhep.2011.08.025. View

10.

Tanaka N, Matsubara T, Krausz K, Patterson A, Gonzalez F . Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis. Hepatology. 2012; 56(1):118-29. PMC: 6371056. DOI: 10.1002/hep.25630. View

11.

Ferslew B, Xie G, Johnston C, Su M, Stewart P, Jia W . Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis. Dig Dis Sci. 2015; 60(11):3318-28. PMC: 4864493. DOI: 10.1007/s10620-015-3776-8. View

12.

Jiao N, Baker S, Chapa-Rodriguez A, Liu W, Nugent C, Tsompana M . Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut. 2017; 67(10):1881-1891. DOI: 10.1136/gutjnl-2017-314307. View

13.

Cai X, Young G, Xie W . The xenobiotic receptors PXR and CAR in liver physiology, an update. Biochim Biophys Acta Mol Basis Dis. 2021; 1867(6):166101. PMC: 8026720. DOI: 10.1016/j.bbadis.2021.166101. View

14.

Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M . A G protein-coupled receptor responsive to bile acids. J Biol Chem. 2003; 278(11):9435-40. DOI: 10.1074/jbc.M209706200. View

15.

Afonso M, Rodrigues P, Simao A, Ofengeim D, Carvalho T, Amaral J . Activation of necroptosis in human and experimental cholestasis. Cell Death Dis. 2016; 7(9):e2390. PMC: 5059878. DOI: 10.1038/cddis.2016.280. View

16.

Keitel V, Stindt J, Haussinger D . Bile Acid-Activated Receptors: GPBAR1 (TGR5) and Other G Protein-Coupled Receptors. Handb Exp Pharmacol. 2019; 256:19-49. DOI: 10.1007/164_2019_230. View

17.

Schaap F, Trauner M, Jansen P . Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol. 2013; 11(1):55-67. DOI: 10.1038/nrgastro.2013.151. View

18.

Russell D . The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem. 2003; 72:137-74. DOI: 10.1146/annurev.biochem.72.121801.161712. View

19.

Schmucker D, Ohta M, Kanai S, Sato Y, Kitani K . Hepatic injury induced by bile salts: correlation between biochemical and morphological events. Hepatology. 1990; 12(5):1216-21. DOI: 10.1002/hep.1840120523. View

20.

Stellaard F, Sackmann M, Berr F, Paumgartner G . Simultaneous determination of pool sizes and fractional turnover rates, of deoxycholic acid, cholic acid and chenodeoxycholic acid in man by isotope dilution with 2H and 13C labels and serum sampling. Biomed Environ Mass Spectrom. 1987; 14(11):609-11. DOI: 10.1002/bms.1200141106. View